CD8A and neoplasm: In our previous study, a potential relationship was found between mutations in the Notch signaling pathway, tumor‐infiltrating CD8+ T cells, and PD‐L1 expression, suggesting enhanced antitumor immunity that could benefit patients with recurrent or metastatic OSCC receiving immune checkpoint inhibitor (ICI) therapy [18].